Gastric intestinal metaplasia regression in United States population: A retrospective longitudinal study
- PMID: 39161796
- PMCID: PMC11331334
- DOI: 10.1002/jgh3.70005
Gastric intestinal metaplasia regression in United States population: A retrospective longitudinal study
Abstract
Background and aim: Gastric cancer is a health concern and contributes to cancer-related deaths. Gastric intestinal metaplasia (GIM) is a premalignant lesion of gastric cancer. Currently, factors associated with GIM regression are under-investigated. This study aims to assess the rate of GIM regression and identify factors associated with it.
Methods: This study was conducted at Medstar Washington Hospital Center. We included patients who had GIM between January 2015 and December 2020. Population was divided into GIM persistence or regression. Data included demographics, esophagogastroduodenoscopy findings, Helicobacter pylori status, and laboratory results. Statistical analyses included Kaplan-Meier and Cox proportional models to explore predictors of GIM regression.
Results: Among 2375 patients, 9.1% had GIM. Notably, 85 patients had GIM regression and 132 patients had persistent GIM. African Americans constituted (75%) of the regression group and (76%) of the persistence group. Peptic ulcer disease (PUD) was noted in 12.9% of the regression group at baseline, and 5.9% at follow-up; the persistence group showed 11.4% at baseline and 5.3% at follow-up (P = 0.89). Regression analysis revealed that the presence of PUD was associated with a higher rate of regression (hazard ratio [HR] 2.46, P = 0.013). Smoking status showed lower rates of regression (HR 0.54 and 0.62, P = 0.038 and 0.169). On gastric mapping, African Americans, Hispanics, and individuals of other races/ethnicities displayed lower rates of GIM regression (HR 0.68, 0.78 and 0.69).
Conclusion: PUD was associated with a higher rate of GIM regression, while smoking showed lower regression rates. Results provide insights into factors influencing GIM regression in African American population and may inform future surveillance and treatment strategies.
Keywords: African American; gastric cancer; gastric intestinal metaplasia; gastric intestinal metaplasia regression; gastric mapping; peptic ulcer disease.
© 2024 The Author(s). JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Figures
Similar articles
-
Gastric intestinal metaplasia development in African American predominant United States population.World J Gastrointest Endosc. 2022 Oct 16;14(10):597-607. doi: 10.4253/wjge.v14.i10.597. World J Gastrointest Endosc. 2022. PMID: 36303812 Free PMC article.
-
Predicting Gastric Intestinal Metaplasia in a High-Risk Population.Cureus. 2022 Nov 14;14(11):e31502. doi: 10.7759/cureus.31502. eCollection 2022 Nov. Cureus. 2022. PMID: 36532909 Free PMC article.
-
Risk of Gastric Cancer Among Patients With Intestinal Metaplasia of the Stomach in a US Integrated Health Care System.Clin Gastroenterol Hepatol. 2016 Oct;14(10):1420-5. doi: 10.1016/j.cgh.2016.05.045. Epub 2016 Jun 16. Clin Gastroenterol Hepatol. 2016. PMID: 27317852
-
Update on the Diagnosis and Management of Gastric Intestinal Metaplasia in the USA.Dig Dis Sci. 2019 May;64(5):1079-1088. doi: 10.1007/s10620-019-05526-5. Dig Dis Sci. 2019. PMID: 30771043 Review.
-
Diagnosis and Management of Gastric Intestinal Metaplasia: Current Status and Future Directions.Gut Liver. 2019 Nov 15;13(6):596-603. doi: 10.5009/gnl19181. Gut Liver. 2019. PMID: 31394893 Free PMC article. Review.
References
-
- Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020; 396: 635–648. - PubMed
-
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022; 72: 7–33. - PubMed
-
- Jun JK, Choi KS, Lee HY et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology. 2017; 152: 1319–1328.e7. - PubMed
LinkOut - more resources
Full Text Sources